Apex’s team has been involved in the development of 80+ investigational products and more than 40 new drugs to market.

  1. Diabetes
    • A Double Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCI versus Glimeperide on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness
    • Insulin Glulisine Administered Premeal Vs. Postmeal in Adult Subjects with Type 2 Diabetes Mellitus Receiving Lantus (insulin glargine) as Basal insulin:  A Multicenter, Randomized, Parallel, Open Label Clinical Study
    • A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety and Tolerability of Pioglitazone HCl (Actos) in Combination with TAK-536 in Subjects with Type 2 Diabetes
  2. Hypertension
    • The African-American Study of Kidney Disease and Hypertension (AASK) Trial
    • NAC-MD-01: A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of  Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential Hypertension
  3. Hyperlipidemia
  4. Chronic Kidney Disease
    • CTAP101-CL-3001 Protocol Title (Study Name): A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
    • CP505.1003: A Multi-Center, Double-Blind, Two-Arm, Placebo-Controlled, Randomized Safety And Tolerability Study Of Ctp-499 In Non-Dialysis Patients With Stage 3 Chronic Kidney Disease
  5. Other Studies:
    • Cardiovascular Disease
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Pain Management
    • Neuropathy
    • Gynecology
    • Male Health
    • Ophthalmology
    • Oncology